Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
    • Transcripts
    • AGM Invitations
    • IPOs
  • inderesTV
  • Portfolio
  • Forum
  • Discovery
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Research

Revenio: Let's investigate before we jump to any further conclusions

By Juha KinnunenAnalyst
Revenio Group
Download report (PDF)

A profit warning weighed on the stock yesterday, which was largely justified as earnings growth turned negative. However, on current information, we expect the weakness to be temporary and the company to return to earnings growth next year. With this, the valuation (2024e EV/EBIT 19x) is reasonable after the collapse. However, the surprisingly sharp deceleration keeps risks elevated and raises concerns, which we will address in the Q2 report.

Login required

This content is only available for logged in users

Create account

Revenio is a global provider of comprehensive eye care diagnostic solutions. The group offers fast, user-friendly, and reliable tools for diagnosing glaucoma, diabetic retinopathy, and macular degeneration (AMD). Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as software solutions under the iCare brand. In 2023, the Group’s net sales totaled EUR 96.6 million, with an operating profit of EUR 26.3 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

Read more on company page

Key Estimate Figures03.08.2023

202223e24e
Revenue97.097.5109.6
growth-%23.1 %0.5 %12.4 %
EBIT (adj.)30.926.332.6
EBIT-% (adj.)31.8 %27.0 %29.7 %
EPS (adj.)0.860.740.95
Dividend0.360.310.45
Dividend %0.9 %1.7 %2.4 %
P/E (adj.)44.625.520.1
EV/EBITDA30.616.813.2

Forum discussions

Well, now it’s high time to jump ship. Getinge, Volati, and Revenio all seem to have gotten undeserved appreciation during the corona turmoil...
yesterday
by tankerous
9
Bråsen’s predictions were pretty accurate when he worked as an analyst for DI. Four other companies might also be worth looking into. Swedes...
yesterday
by Matkalle...
8
In Revenio, Bråse sees a severely depressed valuation accelerating growth The picks from this fund manager with “clear” upside potential are...
yesterday
by Opa
7
Spotted on Nordnet, nothing new or amazing, but perhaps people will wake up a bit regarding Revenio:
yesterday
by MTES
19
This is a pretty convincing picture. Halfway to becoming a Dividend Aristocrat. Are the years when the dividend remained the same counted, or...
3/23/2026, 3:16 PM
by Sissos
12
However, this point is interesting: 20. Amendment of Article 4 of the Articles of Association The Board of Directors proposes that Article 4...
3/23/2026, 2:55 PM
by Sissos
34
Revenio Group Revenio Group Oyj: Yhtiökokouskutsu 2026 The notice of the Annual General Meeting (AGM) has now been issued. The AGM will be held...
3/23/2026, 2:50 PM
by Temew
7
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.